CIK 0001933414 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Mineralys Therapeutics, Inc.
Sign in to watch- Ticker
- MLYS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 841966887
- Phone
- (888) 378-6240
- Business address
- 150 N. RADNOR CHESTER ROAD, SUITE F200, RADNOR, PA
- 4 Planned sale Director sold 3,000 shares at $25.00 ($75,000)
- 4 Planned sale Chief Medical Officer sold 8,519 shares at an average $24.20 ($206,151)
- 4 Planned sale Chief Medical Officer sold 417 shares at $27.55 ($11,488)
- 4 Planned sale Chief Medical Officer sold 22,575 shares at an average $28.91 ($652,638)
- 4 Planned sale Chief Medical Officer sold 416 shares at $31.33 ($13,033)
- 4 Planned sale Chief Medical Officer sold 20,406 shares at an average $26.89 ($548,672)
- 4 Planned sale Chief Executive Officer sold 15,730 shares at $26.83 ($421,979)
- 4 Planned sale Chief Medical Officer sold 2,170 shares at $27.38 ($59,415)
- 4 Planned sale Chief Executive Officer sold 75,000 shares at an average $26.27 ($1,970,522)
- 4 Planned sale Director sold 3,000 shares at $25.00 ($75,000)
- 4 Open-market buy Director bought 369,000 shares at an average $23.75 ($8,762,797)
- 4 Planned sale Chief Medical Officer sold 417 shares at $25.65 ($10,696)
- 4 Planned sale Chief Medical Officer sold 20,406 shares at an average $26.61 ($542,973)
- 4 Planned sale Chief Medical Officer sold 2,171 shares at $26.84 ($58,270)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 6,200 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 140,900 shares (grant or award)
- 4 Grant or award Director acquired 6,200 shares (grant or award)
- 4 Grant or award Director acquired 6,200 shares (grant or award)
- 4 Grant or award Director acquired 6,200 shares (grant or award)
Page 2 of 9 · 180 filings